Gemcitabine monophosphate is primarily used in the treatment of various cancers, including pancreatic, lung, breast, and ovarian cancers. It functions as an antimetabolite, interfering with DNA synthesis and inhibiting the growth of cancer cells. In clinical settings, it is often administered intravenously as part of combination chemotherapy regimens to enhance its efficacy. Its ability to target rapidly dividing cells makes it particularly effective in reducing tumor size and slowing disease progression. Additionally, it is sometimes used in palliative care to alleviate symptoms and improve the quality of life for patients with advanced cancer.